Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,308
Next Earnings Date5/7/2019 (Confirmed)
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings results on Thursday, February, 28th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.31. The firm had revenue of $153.39 million for the quarter, compared to analysts' expectations of $164.75 million. Akorn had a negative return on equity of 13.34% and a negative net margin of 57.91%. The company's quarterly revenue was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.14 earnings per share. View Akorn's Earnings History.
When is Akorn's next earnings date?
How can I listen to Akorn's earnings call?
Akorn will be holding an earnings conference call on Tuesday, May 7th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8442499382.
What price target have analysts set for AKRX?
6 analysts have issued 1-year price targets for Akorn's stock. Their predictions range from $4.00 to $11.00. On average, they anticipate Akorn's share price to reach $6.60 in the next twelve months. This suggests a possible upside of 126.8% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
News stories about AKRX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near term.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Prestige Consumer Healthcare (PBH), Opko Health (OPK), Corcept Therapeutics (CORT), Innoviva (INVA), Myovant Sciences (MYOV), Inflarx (IFRX), Phibro Animal Health (PAHC), Cambrex (CBM), Tricida (TCDA), Puma Biotechnology (PBYI), Aimmune Therapeutics (AIMT), Theravance Biopharma (TBPH), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR) and Epizyme (EPZM).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.12%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor and Joseph Bonaccorsi. View Institutional Ownership Trends for Akorn.
Which major investors are buying Akorn stock?
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $2.91.
How big of a company is Akorn?
Akorn has a market capitalization of $365.43 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,308 workers across the globe.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
